Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
Prostate Cancer, Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring Fiducial Marker, MRI, Prostate Cancer, Radiation
Eligibility Criteria
INCLUSION CRITERIA: Pathologically confirmed adenocarcinoma of the prostate gland. Age greater than or equal to 18 years. ECOG performance status of 0 or 1. Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed (this does not include routine laboratory tests or imaging studies required to establish eligibility). EXCLUSION CRITERIA: Patients with contraindication to transrectal needle placement: Bleeding disorder; PT/PTT greater than 1.5.times the upper limit of normal; Platelets less than 50K; Artificial heart valve. Patients with contraindications to MRI: Patients weighing greater than 136 kg (weight limit for scanner table); Patients with pacemakers, cerebral aneurysm clips, shrapnel injury, or implanted electronic devices. Patients with chronic inflammatory bowel disease. Patients with distant metastatic disease. Patients with a prior history of pelvic or prostate radiotherapy. Cognitively impaired patients who cannot give informed consent. Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Arms of the Study
Arm 1
Experimental
1
Placement of fidicual markers under MRI guidance for localization of radiaiton treatment